Glenn Dranoff

Q: What Schools Are Affiliated With Glenn Dranoff

Glenn Dranoff is affiliated with the following schools: Massachusetts General Hospital, Duke University, Harvard University, Hokkaido University, Heinrich Heine University Düsseldorf, University of Melbourne, University of Valencia, Massachusetts Institute of Technology, Johns Hopkins University

Glenn Dranoff's AcademicInfluence.com Rankings

Glenn Dranoff

Philosophy

#5326

World Rank

#8092

Historical Rank

Logic

#2627

World Rank

#3643

Historical Rank

philosophy Degrees

Glenn Dranoff

Biology

#7119

World Rank

#9984

Historical Rank

Immunology

#378

World Rank

#393

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Glenn Dranoff's Degrees

Doctorate Medicine Harvard University

Why Is Glenn Dranoff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Glenn Dranoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer immunotherapy comes of age (2011) (3122)
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. (1993) (2825)
Cytokines in cancer pathogenesis and cancer therapy (2004) (1413)
Combining immunotherapy and targeted therapies in cancer treatment (2012) (1247)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016) (1064)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. (2013) (1025)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003) (979)
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. (1994) (890)
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. (1997) (883)
Prospects for combining targeted and conventional cancer therapy with immunotherapy (2017) (650)
Coinhibitory Pathways in Immunotherapy for Cancer. (2016) (649)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008) (644)
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis (2015) (616)
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. (1998) (591)
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. (2007) (589)
Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites (1998) (581)
Cathepsin S required for normal MHC class II peptide loading and germinal center development. (1999) (532)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. (2006) (529)
Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review (2010) (460)
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. (1997) (453)
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. (2000) (445)
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. (2015) (423)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies (2013) (401)
Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy (2014) (386)
Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype (2009) (383)
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. (1997) (382)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. (2016) (372)
Infection-Mimicking Materials to Program Dendritic Cells In Situ (2008) (361)
Immune therapy for cancer. (2009) (353)
Sequestration of T-cells in bone marrow in the setting of glioblastoma and other intracranial tumors (2018) (341)
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. (2014) (333)
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma (2018) (322)
GM‐CSF‐based cancer vaccines (2002) (315)
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. (2003) (298)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model (2015) (297)
Modeling genomic diversity and tumor dependency in malignant melanoma. (2008) (294)
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. (2003) (280)
Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. (1996) (279)
Cancer immunology—analysis of host and tumor factors for personalized medicine (2011) (274)
Injectable cryogel-based whole-cell cancer vaccines (2015) (266)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity (2018) (254)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma (2008) (251)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy (2014) (242)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade (2017) (237)
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. (1996) (231)
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice (2009) (222)
Demonstration of a rational strategy for human prostate cancer gene therapy. (1994) (214)
Dual roles for immunity in gastrointestinal cancers. (2010) (199)
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. (2000) (196)
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. (2007) (196)
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. (2011) (191)
Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. (1996) (189)
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. (2019) (186)
In vivo discovery of immunotherapy targets in the tumour microenvironment (2014) (184)
Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer (2003) (176)
GM-CSF-secreting melanoma vaccines (2003) (174)
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. (2006) (173)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma (2018) (161)
Immunotherapy advances for glioblastoma. (2014) (158)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
Gene transfer as cancer therapy. (1995) (150)
Nf1 and Gmcsf interact in myeloid leukemogenesis. (2000) (147)
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. (2000) (146)
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. (2015) (143)
High efficiency gene transfer into primary human tumor explants without cell selection. (1993) (132)
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma (2000) (129)
Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model (2012) (127)
Cytokine-secreting tumor cell vaccines. (2000) (126)
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. (2016) (125)
α-CTLA-4 mAb-associated Panenteritis: A Histologic and Immunohistochemical Analysis (2008) (124)
Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade (2017) (122)
Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. (1998) (122)
Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients (2018) (121)
Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. (1997) (120)
IAP inhibitors enhance co-stimulation to promote tumor immunity (2010) (119)
Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. (2011) (118)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. (1997) (115)
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication (2015) (113)
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction (2003) (113)
Experimental mouse tumour models: what can be learnt about human cancer immunology? (2011) (112)
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial (2017) (109)
FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors (2018) (109)
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation (2009) (108)
Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors (2012) (107)
Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. (2001) (106)
Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. (1997) (106)
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia (2001) (106)
Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. (1998) (105)
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte–macrophage colony-stimulating factor-dependent fashion (2003) (103)
Cancer Immunotherapy: Beyond Checkpoint Blockade (2019) (99)
Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. (2008) (99)
Involvement of interleukin-3 in delayed-type hypersensitivity. (1998) (94)
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. (2002) (90)
Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. (1997) (90)
Advances in Therapeutic Cancer Vaccines. (2016) (89)
Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms (2009) (89)
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. (1995) (87)
A dual role for the immune response in a mouse model of inflammation-associated lung cancer. (2011) (87)
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes (2017) (87)
GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. (1997) (87)
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. (2004) (87)
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. (2001) (85)
Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. (2014) (84)
Gene therapy of metastatic cancer by in vivo retroviral gene targeting (1995) (82)
Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines (2008) (80)
Macrophage Growth Factors Introduced into the Kidney Initiate Renal Injury (1996) (77)
Active immunotherapy induces antibody responses that target tumor angiogenesis. (2010) (77)
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts (2020) (76)
A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. (1997) (75)
Cancer gene therapy: connecting basic research with clinical inquiry. (1998) (75)
Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity (2019) (73)
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. (2013) (71)
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 (2017) (69)
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes (2016) (68)
Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. (1998) (67)
IL-3 is required for increases in blood basophils in nematode infection in mice and can enhance IgE-dependent IL-4 production by basophils in vitro (2008) (66)
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation (2015) (64)
Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. (1994) (63)
Capitalizing on the Immunogenicity of Dying Tumor Cells (2008) (63)
Drug Discovery for Kinetoplastid Diseases: Future Directions. (2018) (62)
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma (2013) (62)
Combinatorial cancer immunotherapy. (2006) (57)
A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients (2014) (55)
Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes (2017) (55)
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction (2002) (51)
Prostate Cancer Immunotherapy (2011) (51)
A word of caution in the use of neuron-specific enolase expression in tumor diagnosis. (1984) (51)
Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection (2017) (51)
Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity. (2001) (50)
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice (2016) (50)
Influence of glutamine on the growth of human glioma and medulloblastoma in culture. (1985) (49)
CTLA-4 blockade: unveiling immune regulation. (2005) (49)
The Therapeutic Implications of Intratumoral Regulatory T Cells (2005) (48)
CD1d and CD1d‐restricted iNKT‐cells play a pivotal role in contact hypersensitivity (2005) (46)
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma (2016) (43)
Inciting inflammation: the RAGE about tumor promotion (2008) (43)
In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. (2002) (42)
Targets of Protective Tumor Immunity (2009) (41)
Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. (2002) (41)
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. (2018) (40)
The biologic importance of tumor‐infiltrating lymphocytes (2010) (39)
Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology (2013) (38)
Role of GM-CSF signaling in cell-based tumor immunization. (2009) (38)
Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity (2013) (37)
Identification and characterization of an alternative cancer-derived PD-L1 splice variant (2019) (37)
A cell surface marker gene transferred with a retroviral vector into CD34+ cord blood cells is expressed by their T-cell progeny in the SCID-hu thymus. (1996) (36)
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. (2009) (35)
MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. (2003) (33)
GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. (1997) (33)
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses (2017) (33)
IL-7 Induces Myelopoiesis and Erythropoiesis1 (2007) (32)
Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma (2016) (32)
MicroRNA MIR21 and T Cells in Colorectal Cancer (2015) (32)
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. (2012) (32)
A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma (2014) (32)
Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response (2018) (31)
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity (2008) (31)
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. (2007) (31)
Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines (2015) (29)
Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. (2002) (29)
High-Resolution Array CGH and Gene Expression Profiling of Alveolar Soft Part Sarcoma (2014) (28)
Role of granulocyte/macrophage colony-stimulating factor in zymocel-induced hepatic granuloma formation. (2001) (26)
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia (2019) (23)
A vaccine targeting resistant tumours by dual T cell plus NK cell attack (2022) (23)
Vaccines and melanoma. (2014) (23)
Immune recognition and tumor protection (2002) (23)
NF-κB Fans the Flames of Lung Carcinogenesis (2010) (22)
Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. (1985) (22)
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells (2017) (22)
Coordinated tumor immunity. (2003) (21)
Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy (2004) (21)
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. (2001) (21)
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells (2014) (21)
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. (2009) (20)
Immunotherapy of Cancer (2012) (20)
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms (2021) (20)
The Immune Response to Tumors (2009) (20)
PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF (2018) (19)
Anti-angiogenesis immunotherapy (2011) (19)
General Discussion 3 (1994) (17)
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. (2017) (17)
A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy (1997) (17)
Strategies for cancer gene therapy. (1997) (16)
The use of gene transfer in cancer immunotherapy. (1998) (16)
CSF‐1 regulation of I6 gene expression by murine macrophages: a pivotal role for GM‐CSF (1998) (16)
Colon stroma mediates an inflammation-driven fibroblastic response controlling matrix remodeling and healing (2022) (15)
Detecting T-cell reactivity to whole cell vaccines (2012) (15)
Genetically modified tumor cell vaccines. (1998) (14)
Coordinated tumor immunity (2003) (14)
GM-CSF-independent CD1a expression in epidermal Langerhans cells: evidence from human CD1A genome-transgenic mice. (2012) (13)
An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. (2020) (13)
Interpreting cancer vaccine clinical trials (1999) (12)
A Model for Selecting Short-Term Tests of Carcinogenicity (1983) (11)
Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions (2014) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Triggering Tumor Immunity through Angiogenesis Targeting (2007) (10)
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors (2015) (10)
A phase I study of vaccination with lethally irradiated, autologous nonsmall cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (2000) (9)
Interleukin-3 and c-Kit/stem cell factor are required for normal eosinophil responses in mice infected with Strongyloides venezuelensis (2006) (9)
Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice. (2011) (8)
Granulocyte-macrophage colony stimulating factor and inflammatory bowel disease: establishing a connection. (2011) (8)
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor (2022) (8)
A gene transfer system establishes interleukin-6 neither promotes nor suppresses renal injury. (1996) (8)
Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 (2017) (8)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy (2020) (7)
Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells (2005) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity (2020) (7)
Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy. (2014) (7)
IL-7 Induces Myelopoiesis and Erythropoiesis (2007) (6)
Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors (2019) (6)
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). (2004) (6)
Gene therapy 1996. (1997) (4)
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers (2022) (4)
Tailor-made renal cell carcinoma vaccines. (2012) (4)
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. (2023) (4)
Cytokine-Based Gene Therapy for Brain Tumors (1998) (4)
Intensifying tumour immunity through combination therapy. (2012) (4)
IT-29IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY (2014) (4)
Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. (2022) (4)
The Cloning of GM-CSF (2017) (3)
Tumour immunology. (2013) (3)
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial (2021) (3)
Immunologic profiling of adenoid cystic carcinoma (acc) (2015) (3)
Immunosurveillance: Innate and Adaptive Antitumor Immunity (2007) (3)
GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML). (2006) (3)
GM-CSF secreting leukemia cell vaccinations after allogeneic non-myeloablative peripheral blood stem cell transplantation in patients with advanced myelodysplastic syndrome or refractory acute myeloid leukemia (2006) (3)
A MODEL FOR SELECTING SHORT‐TERM TESTS OF CARCINOGENICITY (1983) (2)
Immunologically active cryogels for breast cancer therapy (P4329) (2013) (2)
59: GM-CSF secreting leukemia cell vaccinations after allogeneic reduced-intensity peripheral blood stem cell transplantation (SCT) for advanced myelodysplastic syndrome (MDS) or refractory acute myeloid leukemia (AML) (2007) (2)
CHAPTER 21 – Granulocyte–macrophage colony-stimulating factor (2003) (2)
Abstract 2343: The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules (2016) (2)
Gene transfer of macrophage growth factors into the kidney of lpr mice initiates renal injury. (1996) (2)
Chapter 8 – Immunosurveillance: Innate and Adaptive Antitumor Immunity (2013) (2)
Cancer immunology and immunotherapy (2011) (2)
Tumor Immunology (2016) (2)
Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers (2018) (2)
An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. (2021) (1)
Abstract 5640: Targeting tumor-promoting inflammation (TPI) via the IL-1βpathway for cancer immunotherapy (2020) (1)
A Message from the Founding Editor-in-Chief (2013) (1)
Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors. (2013) (1)
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model (2022) (1)
Therapeutics , Targets , and Chemical Biology CXCL 12 / CXCR 4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer (2011) (1)
The Therapeutic Implications of Intratumoral Regulatory TCells 55 Commentary on Wolf et al . p . 8326 (2005) (1)
Cancer Immunology Research: A One-Year Anniversary (2014) (1)
GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies (2008) (1)
Faculty Opinions recommendation of A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. (2002) (1)
Malignant Melanoma Modeling Genomic Diversity and Tumor Dependency in Updated (2008) (1)
GM-CSF and Whole Cells (2013) (1)
Patients with Malignant Glioma CD 4 Compartment Explains Cellular Immune Defects in Increased Regulatory T-Cell Fraction Amidst a Diminished (2006) (1)
Targeting gene therapy--a reality? (2000) (1)
Early Post-Transplant Whole Tumor Cell Vaccination Elicits Anti-Tumor T Cell Responses in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) (2011) (1)
Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) (2012) (0)
Tumor vaccines (WS-070) Chairpersons: Yutaka Kawakami, Olivera Finn (2010) (0)
Faculty Opinions recommendation of Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. (2003) (0)
e- Blood Compartment-speciﬁc bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function (2012) (0)
Abstract LB-387: Blockade of the CXCL12/CXCR4 axis with AMD3100 induces multimodal antitumor effects in murine ovarian cancer and prolongs survival (2011) (0)
260 Investigating cancer cell autonomous CAR T cell therapy resistance in DLBCLin vitro (2022) (0)
Faculty Opinions recommendation of Lymphocyte-mediated immunosurveillance of epithelial cancers? (2001) (0)
OX86 mediates depletion of OX40-expressing intratumoral regulatory T cells through Fc receptor co-engagement, leading to potent anti-tumor efficacy (2014) (0)
Abstract IA8: The interplay of inflammation and cancer. (2013) (0)
Injectable Cryogel-based Whole Cell Cancer Vaccines Please share how this access benefits you. Your story matters (2019) (0)
Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production Deficient Mice: No Physiologic - mpl Cytokine Production and Function in c- (2011) (0)
130 INFLUENCE OF GLUTAMINE ON GROWTH OF HUMAN MEDULLOBLASTOMA IN CULTURE (1984) (0)
Safety And Clinical Efficacy Of Early Vaccination After Nonmyeloablative Transplant For Advanced Chronic Lymphocytic Leukemia (2010) (0)
Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint (2015) (0)
Advances in Brief Protective Immunity Induced by Tumor Vaccines Requires Interaction between CD 4 Oand Its Ligand , CD 1541 (2006) (0)
Abstract PL07-03: Mechanisms of protective tumor immunity. (2013) (0)
Cancer Immunology Essentials: A Preface (2014) (0)
Balancing tumor immunity and inflammation (2008) (0)
Immune monitoring of antibody responses to complex immunotherapies using custom protein microarrays (2008) (0)
A novel iNKT cell-mediated vaccine maneuver induces potent long-lasting anti-tumor immunity for advanced prostate cancer by boosting CD8+T cell memory and function (53.24) (2012) (0)
Cancer Immunology Research: A Two-Year Anniversary (2014) (0)
Faculty Opinions recommendation of Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. (2007) (0)
Comprar Cancer Immunology And Immunotherapy (Current Topics In Microbiology And Immunology, Vol. 344) | Glenn Dranoff | 9783642141355 | Springer (2010) (0)
Abstract P2-15-03: A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine (2015) (0)
colony-stimulating factor or interleukin-3 oncogenes does not require granulocyte-macrophage Induction of myeloproliferative disease in mice by tyrosine kinase fusion (2013) (0)
Faculty Opinions recommendation of Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. (2002) (0)
Human Cancer Biology High-Resolution Array CGH and Gene Expression Pro fi ling of Alveolar Soft Part Sarcoma (2014) (0)
Abstract B72: Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who received Ipilimumab post GVAX vaccine. (2016) (0)
Faculty Opinions recommendation of Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. (2008) (0)
Abstract #2865: The role of tumor-derived MFG-E8 in triggering chemoresistance and immune suppression in patients with various solid tumors (2009) (0)
Faculty Opinions recommendation of Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. (2007) (0)
cells β factor and interleukin-3 contribute to insulitis and destruction of Functional deficiencies of granulocyte-macrophage colony stimulating (2013) (0)
Abstract A56: Identification and characterization of an alternative cancer-derived PDL1 isoform (2017) (0)
Faculty Opinions recommendation of Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. (2004) (0)
Faculty Opinions recommendation of The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma. (2005) (0)
198 Of Mice and Men: Matched Observations of Lymphopenia, Splenic Retraction, and the Bone Marrow as Harbor for Lost T-cells in Mice and Patients With Glioblastoma (2013) (0)
Cancer Immunotherapy: The Road to Rejection (2015) (0)
Targeting the IL-1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. (2023) (0)
Abstract C103: Targeting IL-1β pathway for cancer immunotherapy (2019) (0)
Abstract SY27-04: Engineering improved cancer vaccines. (2013) (0)
Balancing tumor immunity and autoimmunity (2006) (0)
Koyama et al-2016-Nat Commun - supplement (2016) (0)
Molecular Profiling of Alveolar Soft Part Sarcoma 1 High resolution array CGH and gene expression profiling of alveolar soft part sarcoma (2013) (0)
IMMU-04. IMMUNOPHENOTYPING OF PEDIATRIC BRAIN TUMORS: CORRELATING IMMUNE INFILTRATE WITH HISTOLOGY, MUTATIONAL LOAD, AND SURVIVAL AND ASSESSING CLONAL T CELL RESPONSE (2017) (0)
Isolation of human anti-MICA antibody from cancer patients responding to immunotherapies. (2012) (0)
Abstract 2936:In situantitumor immunotherapy with pharmacological blockade of MFG-E8 and chemotherapy against solid and hematological tumors (2010) (0)
Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer (2012) (0)
Abstract IA23: Microenvironmental regulation of antitumor immune responses: A lesson from fibroblastic cells (2016) (0)
Faculty Opinions recommendation of IL-23 promotes tumour incidence and growth. (2006) (0)
Faculty Opinions recommendation of CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. (2008) (0)
Abstract IA25: Mechanisms of protective tumor immunity (2015) (0)
Abstract PR03: Molecular characterization of in vitro exhausted T cells (2017) (0)
Abstract 1355: Functional inactivation of LKB1 increases the production of pro-inflammatory cytokines and governs response to immune modulation (2015) (0)
TB-03IMMUNOPHENOTYPING OF PEDIATRIC BRAIN TUMORS: CORRELATING IMMUNE INFILTRATE WITH HISTOLOGY, MUTATIONAL LOAD, AND SURVIVAL (2016) (0)
A vaccine targeting resistant tumours by dual T cell plus NK cell attack (2022) (0)
Unexpected Functions of Granulocyte-Macrophage Colony Stimulating Factor (1996) (0)
Influence of Glutamina on the Growth of Human Glioma and Medulloblastoma in Culture1 (2006) (0)
Abstract 497: Engagement of activatory Fc γ receptors by immunoregulatory receptor-targeting antibodies mediates antitumor activity. (2013) (0)
Interleukin-3 Contribute to Insulitis and Destruction of β-Cells Short title: GM-CSF, IL-3 and Diabetes (2013) (0)
TriggeringTumor Immunity through AngiogenesisTargeting 55 Commentary onManning et al . , p . 3951 (2007) (0)
Abstract 638: Lenalidomide treatment enhances the anti-tumor activities of XBP1 specific cytotoxic T lymphocytes by increasing the frequency and tumor-specific response of central memory CD3+CD8+ T cells (2014) (0)
The Interplay of Inflammation and Cancer (2011) (0)
Faculty Opinions recommendation of Adaptive immunity maintains occult cancer in an equilibrium state. (2007) (0)
Abstract PL04-03: Engineering improved cancer vaccines. (2011) (0)
Abstract 3210: An in vitro approach to study T cell exhaustion (2016) (0)
Abstract B79: Proinflammatory cytokine profile of syngeneic models (2020) (0)
Principles of Targeted Immunotherapy (2015) (0)
Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function (2010) (0)
A New Cancer Immunology Research Special Feature: Perspective from a Master of Immunology (2014) (0)
IMMU-23. IMMUNOPHENOTYPING OF PEDIATRIC BRAIN TUMORS: CORRELATING IMMUNE INFILTRATE WITH HISTOLOGY, MUTATIONAL LOAD, AND SURVIVAL AND ASSESSING CLONAL T CELL RESPONSE. (2017) (0)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors (2018) (0)
TriggeringTumor Immunity through AngiogenesisTargeting (2007) (0)
acute pancreatitis-associated lung injury In vivo evidence for the role of GM-CSF as a mediator in (2016) (0)
Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention (2009) (0)
Advanced Vaccine Research Methods for the Decade of Vaccines (2015) (0)
New recruit has big dreams for cancer immunotherapy (2019) (0)
Faculty Opinions recommendation of Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. (2001) (0)
G-CSF, GM-CSF, and IL-3 Knockout Mice (2003) (0)
Faculty Opinions recommendation of Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. (2007) (0)
Metabolic Network 10-24-2017 Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection (2018) (0)
A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. (2009) (0)
Infection-mimicking materials to regulate dendritic cell subsets and T cell in situ for cancer vaccination (P4324) (2013) (0)
Faculty Opinions recommendation of TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. (2004) (0)
Abstract A76: Anti IL-1b as a cancer immunotherapy (2020) (0)
hypersensitivity and interleukin-3 in eosinophil homeostasis and contact Overlapping roles for granulocyte-macrophage colony-stimulating factor (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Glenn Dranoff?

Glenn Dranoff is affiliated with the following schools:

Glenn Dranoff's Academic­Influence.com Rankings

Glenn Dranoff's Degrees

Why Is Glenn Dranoff Influential?

Glenn Dranoff's Published Works

Published Works

What Schools Are Affiliated With Glenn Dranoff?

Glenn Dranoff's AcademicInfluence.com Rankings